 |
|
|
| |
Efficacy and safety of sofosbuvir/velpatasvir in people with chronic
hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-22 Amsterdam Netherlands
Jason Grebely1, Olav Dalgard2, Brian Conway3, Evan Cunningham1, Philip Bruggmann4, Behzad Hajarizadeh1, Janaki Amin1, Pip Marks1, Sophie Quiene1, Tanya L. Applegate1, Tracy Swan5, Jude Byrne6, Melanie Lacalamita7, Adrian J. Dunlop8, Julie Bruneau9, Margaret E. Hellard10, Gail V. Matthews1, Jeff Powis11, David Shaw12, Christine M. Thurnheer7, Martin Weltman13, Ian Kronborg14, Curtis Cooper15, Jordan J. Feld16, Chris Fraser17, Alain Litwin18, John Dillon19, Phillip Read20, Ed Gane21, Gregory J. Dore1 on behalf of the SIMPLIFY Study Group
1The Kirby Institute, UNSW Sydney, Sydney, Australia, 2Akershus University Hospital, Oslo, Norway, 3Vancouver Infectious Diseases Center, Vancouver, Canada, 4Arud Centres for Addiction Medicine, Zurich, Switzerland, 5Medecins Sans Frontières, New York, United States, 6Australian Injecting & Illicit Drug Users League, Canberra, Australia, 7Poliklinik fur Infektiologie, Inselspital, Bern, Switzerland, 8Newcastle Pharmacotherapy Service, Newcastle, Australia, 9Centre Hospitalier de l'Universite de Montreal, Montreal, Canada, 10The Burnet Institute, Melbourne, Australia, 11South Riverdale Community Health Centre, Toronto, Canada, 12Royal Adelaide Hospital, Adelaide, 13Nepean Hospital, Penrith, 14Footscray Hospital, Footscray, Australia, 15Ottawa Hospital Research Institute, Ottawa, 16Toronto General Hospital, Toronto, 17Coolaid Community Health Centre, Victoria, Canada, 18Montefiore Medical Centre, New York, United States, 19Ninewells Hospital, Dundee, United Kingdom, 20Kirketon Road Centre, Sydney, Australia, 21Auckland Hospital, Auckland, New Zealand
|
| |
|
|
|
|
|
